Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $51.21.

A number of equities analysts have issued reports on KYMR shares. Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Truist Financial reaffirmed a “buy” rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Finally, Oppenheimer raised their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its holdings in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after acquiring an additional 295 shares in the last quarter. Comerica Bank raised its holdings in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares in the last quarter. Keudell Morrison Wealth Management raised its holdings in Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after buying an additional 480 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after buying an additional 915 shares in the last quarter.

Kymera Therapeutics Price Performance

KYMR opened at $41.96 on Friday. Kymera Therapeutics has a 12 month low of $16.94 and a 12 month high of $53.27. The stock has a market cap of $2.72 billion, a P/E ratio of -17.93 and a beta of 2.21. The stock’s 50 day moving average price is $47.17 and its 200 day moving average price is $41.62.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same period last year, the firm earned ($0.90) EPS. The firm’s revenue was down 20.9% compared to the same quarter last year. Equities analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.